Danish researchers report that elevated serum levels of the macrophage-derived protein soluble CD163 independently predict ...

Sanoj Punnen, M.D., a urologic oncologist at Sylvester Comprehensive Cancer Center and Vice Chair of Research at Desai Sethi Urology Institute, part of UHealth, the University of Miami Health System, ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

Resero Bio, a precision diagnostics company building a cell-free RNA (cfRNA) liquid biopsy platform, today announced publication of a Stanford-led study in Nature Medicine demonstrating that analysis ...

Nowon Eulji University Hospital, led by Hospital Director Kim Jae-hoon, said its Department of Urology reviewed the clinical ...

Prostate cancer screening generally begins around age 50, while men at higher risk may consider starting earlier, closer to ...

EHS leadership encouraged men to get regular screenings, which the hospital provides periodically throughout the year for ...

When prostate cancer returns or is at high risk of returning after surgery, radiation to the prostate bed (the area where the prostate used to be) is often recommended. The standa ...

For the hundreds of thousands of men who undergo radical prostatectomy each year, one question looms over every postoperative ...

At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence ...

Medicana Health Group is highlighting the role of robot-assisted surgery in prostate cancer treatment as a 2026 research ...